DURHAM

Validic named “Best Remote Patient Monitoring Solution” in 8th Annual MedTech Breakthrough Awards Program

Retrieved on: 
Thursday, May 9, 2024
Medtech, Glycated hemoglobin, RPM, Ecosystem, SBP, Health, Cardiology, EHR, Electronic health record, Telehealth, Medical device, Patient, Hypertension, Remote patient monitoring, Nursing

DURHAM, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Validic Inc. , a market-leading digital health and personalized care company, today announced it has been selected as “Best Remote Patient Monitoring Solution” in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.

Key Points: 
  • DURHAM, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Validic Inc. , a market-leading digital health and personalized care company, today announced it has been selected as “Best Remote Patient Monitoring Solution” in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.
  • “Validic exceeds these expectations, with a breakthrough solution that puts patient data where clinicians need it, and it fits within their existing care models.
  • Blending in-person and remote care, as well as personal health data from devices, ultimately creates a new standard of care.
  • We extend our sincere congratulations to the Validic team on their well-deserved 2024 MedTech Breakthrough Award.”

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

Retrieved on: 
Thursday, May 9, 2024
University, International Society, Poster, BioCryst Pharmaceuticals, LTP, MD, History, Documentation, Hereditary angioedema, Patient, Medicine, HRU, HAE, Pharmacoeconomics, Disease, Pharmaceutical industry

“The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.

Key Points: 
  • “The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.
  • This outcome provides a compelling argument that ORLADEYO, which is known to be effective in reducing HAE morbidity, is also a cost-effective strategy for patient management.
  • The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States.
  • We look forward to reporting additional real-world evidence that highlights the benefits associated with long-term prophylaxis with ORLADEYO,” said Dr. William Sheridan, chief development officer and interim chief medical officer of BioCryst.

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
Wednesday, May 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

Aerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International Conference

Retrieved on: 
Wednesday, May 8, 2024
DPI, Inhalation, ATS, Pulmonary hypertension, RDA, MD, PAH, Conference, Orthostatic hypertension, Functional, FRI, American Thoracic Society, Pharmaceutical industry

One presentation will feature new lung deposition modeling data comparing the deposition of AER-901 to that of a hypothetical dry powder inhaled (DPI)-imatinib in subjects with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), as well as healthy volunteers.

Key Points: 
  • One presentation will feature new lung deposition modeling data comparing the deposition of AER-901 to that of a hypothetical dry powder inhaled (DPI)-imatinib in subjects with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), as well as healthy volunteers.
  • These modeling data were generated by FLUIDDA, Inc., using their proprietary Functional Respiratory Imaging (FRI) And Rapid Deposition Analysis (RDA) platforms.
  • In addition, the unique and innovative design of the “uniPHied” platform Phase 2 trial will be presented, demonstrating the optionality to expeditiously evaluate AER-901 in multiple pulmonary hypertension cohorts (initially PH-ILD and PAH).
  • "We are excited to present new lung deposition modeling data that we believe strongly support the differentiation of AER-901 and its potential to reverse the vascular remodeling process central to multiple forms of pulmonary hypertension," said Gary Burgess, MD, Chief Medical Officer of Aerami.

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Retrieved on: 
Tuesday, May 7, 2024
News, Calendar, Software, Webcast, PIN

To access the conference call, please register using https://register.vevent.com/register/BI137d97d6710341398d6f17d0433dc5b8 .

Key Points: 

Bioventus Reports First Quarter Financial Results

Retrieved on: 
Tuesday, May 7, 2024
Surgery, Growth, Pharmaceutical industry

DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024.

Key Points: 
  • DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024.
  • "As we look ahead, we remain laser focused on executing on our priorities to accelerate revenue growth, enhance profitability and reduce our leverage.
  • The increase in our financial guidance signals the confidence we have in our ability to build on our momentum throughout 2024 and create further value for our stakeholders.”
    First Quarter 2024 Financial Results:
    For the first quarter, worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period.
  • Loss per share of Class A common stock from continuing operations was $0.07 in the first quarter, compared to a loss of $1.28 in the prior-year period.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 7, 2024
BioCryst Pharmaceuticals, Bank, Conference

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
    Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m.
  • 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m.
  • Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m.

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

Retrieved on: 
Tuesday, May 7, 2024
Telephone

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024.
  • The Company will host a conference call to discuss these results starting at 4:30 p.m.
  • To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time.
  • To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations .

Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference Call

Retrieved on: 
Monday, May 6, 2024

DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an updated issuance date for the company’s first quarter 2024 financial results.

Key Points: 
  • DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an updated issuance date for the company’s first quarter 2024 financial results.
  • Fortrea will now release its first quarter 2024 financial results before the market opens on Monday, May 13, 2024, rather than on Tuesday, May 7, 2024, as previously announced.
  • The company will host a conference call at 8:00 am ET on the date of release to review its financial results and conduct a question-and-answer session.
  • To participate in the earnings call, participants should register online at the Fortrea Investor Relations website .

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 6, 2024
Net, Skin, Investment, Solubility, Research, Diabetes, BioCryst Pharmaceuticals, Plasma, Injection, Webcast, Kallikrein, Prescription, Disease, Dehydration, Patient, Eye, Operating cost, Physician, Paratriathlon, EPS, Workforce, Infection, DME, Clinical trial, HAE, Diabetic retinopathy, Edema, Genetic disorder, GAAP, Netherton syndrome, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • These two successes helped us exceed our revenue projections for the quarter and, as a result, we are increasing our revenue guidance for 2024,” said Charlie Gayer, chief commercial officer of BioCryst.
  • Interest expense was $24.5 million in the first quarter of 2024, compared to $27.4 million in the first quarter of 2023 (-10.6 percent y-o-y).
  • Our references to our first quarter 2024 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures.
  • ET today to discuss the financial results and provide a corporate update.